Summary. Anxiety disorders are among the leading contributors to global disability and frequently co-occur with major depressive disorder (MDD), chronic pain, and various psychiatric or somatic comorbidities. Effective management of these conditions necessitates a personalized approach informed by current scientific evidence. Extended-release (XR) venlafaxine, a serotonin-noradrenaline reuptake inhibitor, has emerged as a first-line pharmacological option, endorsed by international guidelines for generalized anxiety disorder, panic disorder, and social anxiety disorder. Its dose-dependent dual mechanism, initially serotonergic, progressing to noradrenergic, enables tailored therapeutic strategies aligned with symptom severity. This narrative review, integrating Italian expert consensus and recent literature, highlights the robust efficacy of XR venlafaxine across anxiety disorders, its favorable tolerability profile due to the osmotic pump zero-order release formulation, and its unique capacity to address residual symptoms such as anhedonia and SSRI-induced emotional blunting. Emerging evidence suggests additional roles for venlafaxine in immunomodulation and the promotion of neuroplasticity, which may further enhance its therapeutic benefit. Given the established role of XR venlafaxine as a key therapeutic option in the pharmacological management of anxiety disorders, and acknowledging the impact of CYP2D6 metabolic variability on its efficacy and tolerability, pharmacogenetic testing could be recommended to optimize treatment personalization. It holds particular promise for patients with comorbid or treatment-resistant profiles, offering measurable benefits in quality of life, functional outcomes, and long-term disease management.
The role of venlafaxine in the modern treatment of anxiety disorders: a critical update and expert clinical perspectives
Camardese, Giovanni;
2026-01-01
Abstract
Summary. Anxiety disorders are among the leading contributors to global disability and frequently co-occur with major depressive disorder (MDD), chronic pain, and various psychiatric or somatic comorbidities. Effective management of these conditions necessitates a personalized approach informed by current scientific evidence. Extended-release (XR) venlafaxine, a serotonin-noradrenaline reuptake inhibitor, has emerged as a first-line pharmacological option, endorsed by international guidelines for generalized anxiety disorder, panic disorder, and social anxiety disorder. Its dose-dependent dual mechanism, initially serotonergic, progressing to noradrenergic, enables tailored therapeutic strategies aligned with symptom severity. This narrative review, integrating Italian expert consensus and recent literature, highlights the robust efficacy of XR venlafaxine across anxiety disorders, its favorable tolerability profile due to the osmotic pump zero-order release formulation, and its unique capacity to address residual symptoms such as anhedonia and SSRI-induced emotional blunting. Emerging evidence suggests additional roles for venlafaxine in immunomodulation and the promotion of neuroplasticity, which may further enhance its therapeutic benefit. Given the established role of XR venlafaxine as a key therapeutic option in the pharmacological management of anxiety disorders, and acknowledging the impact of CYP2D6 metabolic variability on its efficacy and tolerability, pharmacogenetic testing could be recommended to optimize treatment personalization. It holds particular promise for patients with comorbid or treatment-resistant profiles, offering measurable benefits in quality of life, functional outcomes, and long-term disease management.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
